Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890552 · ClinicalTrials.gov registry record · NA
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00890552: Completed NA study, sponsored by Stanford University.
NCT00890552 is a NA study that has completed, run by Stanford University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890552, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890552
The ClinicalTrials.gov registry entry for NCT00890552 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00890552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890552 about?
NCT00890552 is a clinical study titled "A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis". This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
What is the current status of trial NCT00890552?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2009-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00890552?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00890552?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.